144 related articles for article (PubMed ID: 37457220)
1. Glioblastoma management in a lower middle-income country: Nationwide study of compliance with standard care protocols and survival outcomes in Ukraine.
Rozumenko A; Kliuchka V; Rozumenko V; Daschakovskiy A; Fedorenko Z
Neurooncol Pract; 2023 Aug; 10(4):352-359. PubMed ID: 37457220
[TBL] [Abstract][Full Text] [Related]
2. The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care.
Salem A; Hashem SA; Al-Rashdan A; Ezam N; Nour A; Alsharbaji A; Sughayer M; Mohamad I; Elyan M; Addas A; Al-Hussaini M; Almousa A
Hematol Oncol Stem Cell Ther; 2011; 4(3):116-20. PubMed ID: 21982884
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
5. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
[TBL] [Abstract][Full Text] [Related]
6. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
[TBL] [Abstract][Full Text] [Related]
7. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
8. Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database.
Zhu P; Du XL; Zhu JJ; Esquenazi Y
J Neurosurg; 2019 Feb; 132(2):491-502. PubMed ID: 30771780
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma.
Jin MC; Wu A; Xiang M; Azad TD; Soltys SG; Li G; Pollom EL
World Neurosurg; 2019 Aug; 128():e217-e224. PubMed ID: 31009783
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
11. Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis.
Ward ZJ; Scott AM; Hricak H; Abdel-Wahab M; Paez D; Lette MM; Vargas HA; Kingham TP; Atun R
Lancet Oncol; 2020 Aug; 21(8):1077-1088. PubMed ID: 32758462
[TBL] [Abstract][Full Text] [Related]
12. Improving prognosis of glioblastoma in the 21st century: who has benefited most?
Lawrence YR; Mishra MV; Werner-Wasik M; Andrews DW; Showalter TN; Glass J; Shen X; Symon Z; Dicker AP
Cancer; 2012 Sep; 118(17):4228-34. PubMed ID: 22180310
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients.
Zur I; Tzuk-Shina T; Guriel M; Eran A; Kaidar-Person O
Sci Rep; 2020 Jun; 10(1):9595. PubMed ID: 32533126
[TBL] [Abstract][Full Text] [Related]
14. Survival rates and predictors of survival among colorectal cancer patients in a Malaysian tertiary hospital.
Magaji BA; Moy FM; Roslani AC; Law CW
BMC Cancer; 2017 May; 17(1):339. PubMed ID: 28521746
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
16. Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.
Wang T; Pham A; Yoo S; Attenello FJ; Jennelle R; Wagle N; Chang EL; Zada G
World Neurosurg; 2020 May; 137():e213-e220. PubMed ID: 32001415
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
19. Pineal Region Glioblastomas: Clinical Characteristics, Treatment, and Survival Outcome.
Niu X; Wang C; Zhou X; Yang Y; Liu Y; Zhang Y; Mao Q
World Neurosurg; 2021 Feb; 146():e799-e810. PubMed ID: 33186787
[TBL] [Abstract][Full Text] [Related]
20. Butterfly glioblastoma: Clinical characteristics, treatment strategies and outcomes in a population-based cohort.
Bjorland LS; Dæhli Kurz K; Fluge Ø; Gilje B; Mahesparan R; Sætran H; Ushakova A; Farbu E
Neurooncol Adv; 2022; 4(1):vdac102. PubMed ID: 35892046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
